Israeli Scientists Learn Why Most Metastatic Melanoma Patients Don’t Respond to Immunotherapy

Israeli Scientists Learn Why Most Metastatic Melanoma Patients Don’t Respond to Immunotherapy

Sheba Hospital in Tel Aviv. Israeli researchers at Tel Aviv University and Sheba Medical Center say they have discovered why more than half of patients with metastatic melanoma do not respond to immunotherapy cancer treatments. Wielding “proteomics” — an innovative “protein mapping” approach — a team of researchers led […] Click here to view original[…]

AstraZeneca's Imfinzi prolongs survival in aggressive lung cancer

AstraZeneca’s Imfinzi prolongs survival in aggressive lung cancer

FRANKFURT: AstraZeneca ‘s cancer treatment Imfinzi has been shown to prolong survival in a particularly aggressive type of lung cancer by close to three months, as the British drugmaker holds its ground in a crowded field against rival immunotherapy drugs. Imfinzi, when combined with chemotherapy , resulted in a […] Click here to view original[…]